RTTNews | Jun 15, 2021 12:54PM EDT

12:53 Tuesday, June 15, 2021 (RTTNews.com) - Shares of Fusion Pharmaceuticals Inc. (FUSN) are gaining nearly 15% on Tuesday morning after the clinical-stage oncology company reported positive safety and dosimetry results from its early stage study of FPI-1434.

FUSN is currently trading at $9.31, up $1.15 or 14.09%, on the Nasdaq. The stock has traded between $6.61 and $19.00 in the 52-week period.

Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity

"The data from our ongoing clinical study of FPI-1434 presented at SNMMI demonstrated that treatment with our actinium-based targeted alpha therapy was well tolerated, and imaging shows uptake of the drug across multiple tumor types," said Chief Executive Officer John Valliant.

"Importantly, these data supported our ability to initiate the multi-dosing portion of the study, in which we would expect to begin reaching total cumulative levels of radiation necessary to demonstrate anti-tumor activity."

Read the original article on RTTNews ( https://www.rttnews.com/3202533/stock-alert-fusion-pharma-jumps-15.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved